Navigation Links
Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives
Date:12/7/2007

rst-line treatment for UC. LIALDA is indicated for the induction of remission in patients with active, mild to moderate UC. The safety and efficacy of LIALDA have been established for up to eight weeks. LIALDA is the first new formulation in this class to be approved since 2000. LIALDA is the only ulcerative colitis treatment that utilizes MMX(R) Technology. LIALDA with MMX Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic excipients.

Shire has licensed from Giuliani SpA the exclusive rights to develop and commercialize LIALDA in the US, Canada, Europe -- known as MEZAVANT(TM) -- (excluding Italy) and the Pacific Rim. Giuliani SpA retains the development and commercialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the MMX technology.

Important Safety Information for LIALDA

LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond 8 weeks have not been established.

LIALDA is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of LIALDA. Caution should be exercised when treating patients with pyloric stenosis or those allergic to sulfasalazine. Mesalamine has been associated with an acute intolerance syndrome (3 percent of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to distinguish from a flare of inflammatory bowel disease. If acute intolerance syndrome is suspected, prompt withdrawal is required. Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported. Reports of renal impairment have been associated with mesalamine medications. In patients with renal impairment, caution sho
'/>"/>

SOURCE Shire PLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
2. Joint NJ/NY Rally for Addiction Recovery to Be Hub of Events Nationwide
3. Photo: Tanger Outlet Center Shoppers Nationwide can Choose Pink to Fight Breast Cancer
4. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
5. Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During America on the Move Week With the YMCA, September 22-29, 2007
6. NIH/NCI renews and extends nationwide license for Genomatix software and databases
7. 100 Black Men of America, Inc. and American Red Cross Sign National Agreement to Increase Diverse Outreach Nationwide
8. New Website Launches Healthy Vending in Schools Nationwide to Help Combat Childhood Obesity
9. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
10. American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
11. Nationwide independent Taser study results suggest devices are safe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... , ATLANTA, Sept. 8 Craneware, Inc. (AIM: CRW.L), a leader in ... for the year ended June 30, 2009. , , Financial ... of contracted sales in the year totaling $43.2m (FY08: $25.7m), 68% up from the ... increase in revenues to $23.0m (FY08: $18.7m) , ...
... , Senators Bob Dole and Tom Daschle join ... bipartisan agreement in health reform , , ... Health Care Together will host a bipartisan health care forum to ... the health reform debate. The event entitled, "Common Sense Collaboration: ...
... , , , BRISTOL, Va. ... and HealthSouth Corporation (NYSE: HLS ) today announced that ... awarded a certificate of public need (COPN) to open a new ... more patients in Bristol and throughout Southwest Virginia to have access ...
... , , , ... Sept. 8 Reportlinker.com announces that a new market research report ... Gastrointestinal Endoscopy Devices , , ... the US market for Gastrointestinal Endoscopy Devices in Millions of US$ ...
... , , Texas ... Jobs, Improve Patient Access to Care , , ... period filled with wide-ranging local discussion of health care reform, the Texas ... care reform in Washington can help drive momentum and discussion in Texas ...
... , SOMERSET, N.J., Sept. 8 ... of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United ... insomnia characterized by difficulties with falling asleep. EDLUAR is ... is the most prescribed treatment for insomnia. Zolpidem tartrate ...
Cached Medicine News:Health News:Craneware Announces Fiscal Year-End Results 2Health News:Craneware Announces Fiscal Year-End Results 3Health News:Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 3Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 4Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 5Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 2Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 3Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 4Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 5Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 6Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 7Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 8Health News:Texas Kidney Community Expresses Hope DC Health Care Reform Debate Can Help Drive Continued Progress in Texas Opening Needed Dialysis Facilities 2Health News:Texas Kidney Community Expresses Hope DC Health Care Reform Debate Can Help Drive Continued Progress in Texas Opening Needed Dialysis Facilities 3Health News:Meda Introduces EDLUAR(TM), the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication, Zolpidem Tartrate 2Health News:Meda Introduces EDLUAR(TM), the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication, Zolpidem Tartrate 3Health News:Meda Introduces EDLUAR(TM), the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication, Zolpidem Tartrate 4
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Pa., Oct. 29 Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today ... Credit Suisse Healthcare Conference to be held November 10-12, 2010 ... Fickenscher, Chief Financial Officer, is scheduled to present an overview ... ET on Thursday, November 11, 2010. To listen ...
... Calif., Oct. 28 VIVUS, Inc. (Nasdaq: ... Response Letter (CRL) from the U.S. Food and Drug ... the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The ... the NDA cannot be approved in its present form. ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 2FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 4FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 5
Portable shields for your safety and convenience....
The Bronze Metalite Constructed of optical-grade steel with bronze electroplate. Fitted lead side shields that create a seal to the front of the lenses for increased scatter protection....
Full-Height Radiation Barriers provide full-body shielding and reduce eye strain during extended procedures....
Height-Adjustable Mobile X-ray Barrier lets you get close to your patient during special procedures like cardiac cath. 24"H x 36"W viewing panel shields the upper body of one or two people and swivel...
Medicine Products: